"Britain's largest pharmaceuticals company could make up to £1bn from sales of its swine flu vaccine, " ziņo interneti.

"Andrew Witty, GSK's chief executive, refused to apologise for the boost in earnings, pointing out that GSK had invested more than $2.5bn (£1.5bn) in its vaccine development programme over the past few years."